ATE525649T1 - Nachweis von proteinen mit veränderter konformation - Google Patents

Nachweis von proteinen mit veränderter konformation

Info

Publication number
ATE525649T1
ATE525649T1 AT04812753T AT04812753T ATE525649T1 AT E525649 T1 ATE525649 T1 AT E525649T1 AT 04812753 T AT04812753 T AT 04812753T AT 04812753 T AT04812753 T AT 04812753T AT E525649 T1 ATE525649 T1 AT E525649T1
Authority
AT
Austria
Prior art keywords
proteins
detection
altered conformation
prions
conformation
Prior art date
Application number
AT04812753T
Other languages
English (en)
Inventor
Cindy Orser
Anne Grosset
Eugene Davidson
Original Assignee
Adlyfe Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adlyfe Inc filed Critical Adlyfe Inc
Application granted granted Critical
Publication of ATE525649T1 publication Critical patent/ATE525649T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
AT04812753T 2003-12-04 2004-12-03 Nachweis von proteinen mit veränderter konformation ATE525649T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/728,246 US20050026165A1 (en) 2001-05-31 2003-12-04 Detection of conformationally altered proteins and prions
PCT/US2004/040309 WO2005057166A2 (en) 2003-12-04 2004-12-03 Detection of conformationally altered proteins and prions

Publications (1)

Publication Number Publication Date
ATE525649T1 true ATE525649T1 (de) 2011-10-15

Family

ID=34677130

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04812753T ATE525649T1 (de) 2003-12-04 2004-12-03 Nachweis von proteinen mit veränderter konformation

Country Status (7)

Country Link
US (3) US20050026165A1 (de)
EP (2) EP1700096B1 (de)
JP (1) JP4815355B2 (de)
AT (1) ATE525649T1 (de)
AU (2) AU2004297579B2 (de)
CA (1) CA2548812A1 (de)
WO (1) WO2005057166A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040131626A1 (en) * 2001-03-15 2004-07-08 Goldstein Allan L. Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (tb4) analogues, isoforms and other derivatives
US20080096817A1 (en) * 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
US20050026165A1 (en) 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
CA2448981C (en) * 2001-05-31 2014-03-18 Arete Associates Misfolded protein sensor method
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
EP1848831A4 (de) * 2005-01-13 2008-11-05 Novartis Vaccines & Diagnostic Elisa-tests unter verwendung prionspezifischer peptidreagentien
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
BRPI0607350A2 (pt) * 2005-02-15 2009-09-01 Adlyfe Inc método para detecção da presença ou quantidade de uma proteìna erroneamente duplicada em uma amostra e kit
JP5209477B2 (ja) * 2005-09-09 2013-06-12 ノバルティス アーゲー プリオンに特異的なペプトイド試薬
WO2007047815A2 (en) * 2005-10-18 2007-04-26 The Brigham And Women's Hospital, Inc. Diagnosis of transmissible spongiform encephalopathy
AU2006326940B2 (en) 2005-12-22 2012-04-19 Vib Vzw Means and methods for mediating protein interference
US8669418B2 (en) 2005-12-22 2014-03-11 Vib Vzw Means and methods for mediating protein interference
US8673579B2 (en) * 2006-07-28 2014-03-18 Adlyfe, Inc. Peptide probes for diagnostics and therapeutics
CA2689120C (en) * 2007-06-04 2017-07-11 Vib Vzw Targeted induction of aggregation of proteins with cross beta structures
US20090274621A1 (en) * 2008-03-21 2009-11-05 Adlyfe, Inc Use of pyrene to carry non-peptide agents across the blood brain barrier
AU2009226161A1 (en) * 2008-03-21 2009-09-24 Adlyfe, Inc. Use of pyrene to carry peptides across the blood brain barrier
CN102083450A (zh) * 2008-04-30 2011-06-01 诺华有限公司 致病性构象异构体的分析
DE102008037564A1 (de) 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
MX2011007916A (es) * 2009-01-30 2011-11-18 Adlyfe Inc Péptidos conformacionalmente dinámicos.
US20120282169A1 (en) * 2009-11-06 2012-11-08 Adlyfe, Inc. Detection and treatment of traumatic brain injury
JP2014514576A (ja) 2011-04-27 2014-06-19 エイディーライフ インコーポレイティッド アミロイドタンパク質の眼における検出法
US9618524B2 (en) * 2014-03-26 2017-04-11 Plaxgen Inc. Method, composition, isolation and identification of a plaque particle and related biomarker
GB201411616D0 (en) * 2014-06-30 2014-08-13 Cambridge Entpr Ltd Diagnosis and treatment of neurodegenerative disorders
WO2016014908A1 (en) * 2014-07-25 2016-01-28 Academia Sinica Bipartite molecules and uses thereof in treating diseases associated with abnormal protein aggregates
CN104215777B (zh) * 2014-09-18 2016-01-20 首都医科大学宣武医院 一种检测血红蛋白结合磷酸化alpha-突触核蛋白的方法
US10670611B2 (en) 2014-09-26 2020-06-02 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
CN110621688A (zh) 2017-05-09 2019-12-27 非营利性组织佛兰芒综合大学生物技术研究所 用于治疗细菌感染的手段和方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6498017B2 (en) * 1907-11-28 2002-12-24 Evotec Biosystems Ag Method for measuring the association of substructures of pathological protein depositions
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US5434050A (en) * 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
ES2128362T3 (es) * 1991-12-03 1999-05-16 Proteus Molecular Design Fragmentos de proteinas de prion.
US5955343A (en) * 1992-12-28 1999-09-21 Massachusetts Institute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US5565186A (en) * 1994-05-13 1996-10-15 The Regents Of The University Of California Method of detecting prions in a sample and transgenic animal used for same
US5578639A (en) * 1994-07-01 1996-11-26 Warner-Lambert Company PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
BR9610580A (pt) * 1995-09-14 2000-10-24 Univ California Anticorpos especìficos para prpse nativos
US5750361A (en) * 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
JP3745380B2 (ja) * 1996-05-14 2006-02-15 ヴィンアッカー，エルンスト―ルートヴィッヒ プリオンタンパク質に結合し、イソ型ＰｒＰ▲上ｃ▼とＰｒＰ▲上ｓｃ▼を識別することが可能なシャペロン
US20060178302A1 (en) * 1997-02-05 2006-08-10 Northwestern University & The University Of Southern California Amyloid beta protein (globular assembly and uses thereof)
US20010001061A1 (en) * 1997-02-21 2001-05-10 Prusiner Stanley B. Assay for disease related conformation of a protein
US5891641A (en) * 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
WO1999008695A1 (en) * 1997-08-14 1999-02-25 The Regents Of The University Of California FLUORESCENT AMYLOID Aβ PEPTIDES AND USES THEREOF
WO2000006990A2 (en) * 1998-07-27 2000-02-10 Ljl Biosystems, Inc. Apparatus and methods for time-resolved spectroscopic measurements
WO1999041279A2 (en) * 1998-02-13 1999-08-19 Arch Development Corporation Methods and compositions comprising the use of blocked b-amyloid peptide
US6214565B1 (en) * 1998-10-09 2001-04-10 The Regents Of The University Of California Assay for disease related conformation of a protein and isolating same
US5977324A (en) * 1998-02-20 1999-11-02 The Regents Of The University Of California Process for concentrating protein with disease-related conformation
US6750025B1 (en) * 1998-07-09 2004-06-15 V.I. Technologies, Inc. Method of detecting and isolating prion protein and variants thereof
GB2348203B (en) * 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
US20050112607A1 (en) * 1999-01-23 2005-05-26 Bamdad Cynthia C. Rapid and sensitive detection of protein aggregation
EP1169646A2 (de) 1999-01-25 2002-01-09 Minerva Biotechnologies Corporation Schneller und empfindlicher nachweis fehlerhafter proteinaggregation bei neurodegenerativen erkrankungen
US6166187A (en) * 1999-03-05 2000-12-26 The Regents Of The University Of California Method of concentrating prion proteins in blood samples
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
CA2499211A1 (en) * 1999-05-17 2000-11-23 Conjuchem Inc. Modified peptides yy and conjugates thereof
BR0012765A (pt) 1999-07-27 2002-04-02 Imp College Innovations Ltd Peptìdeo, métodos de fabricar um anticorpo, de fabricar um agente de ligação capaz de ligar-se a uma forma celular de uma proteìna de prion, de remover uma forma celular de uma proteìna de prion de uma amostra, e de usar um anticorpo e/ou agente de ligação, anticorpo, agente de ligação, uso de um anticorpo ou agente de ligação, kit, e , sequência de peptìdeo de uma forma celular de uma proteìna de prion
GB9917724D0 (en) * 1999-07-28 1999-09-29 Medical Res Council Peptides
AU7065500A (en) 1999-08-23 2001-03-19 Regents Of The University Of California, The Compounds useful to mimic peptide beta-strands
DE19952955A1 (de) * 1999-11-03 2001-05-17 Acgt Progenomics Ag Verfahren zur Charakterisierung und zur Auftrennung von molekularen Assoziaten
US6399314B1 (en) 1999-12-29 2002-06-04 American Cyanamid Company Methods of detection of amyloidogenic proteins
CA2405568A1 (en) 2000-04-05 2001-10-18 North Carolina State University Prion-binding peptidic ligands and methods of using same
AU6408901A (en) * 2000-07-07 2002-01-21 Applied Research Systems Early diagnosis of conformational diseases
US6780641B2 (en) * 2000-07-10 2004-08-24 University Of British Columbia Immortalized human microglia cell line
US6495335B2 (en) * 2000-12-07 2002-12-17 Mario Chojkier Compositions and methods for diagnosing alzheimer's disease
US7303907B2 (en) * 2001-01-08 2007-12-04 Health Protection Agency Degradation and detection of TSE infectivity
US20050084901A1 (en) 2001-04-17 2005-04-21 Everett Nicholas P. Detection and quantification of prion isoforms in neurodegenerative diseases using mass spectrometry
US6821504B2 (en) * 2001-05-23 2004-11-23 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
CA2448981C (en) * 2001-05-31 2014-03-18 Arete Associates Misfolded protein sensor method
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
CA2451795A1 (en) * 2001-06-26 2003-01-09 Paul M. Mathews Cell-based high-throughput screening methods
AU2002358647A1 (en) * 2001-12-10 2003-06-23 Laboratoires Serono Sa Prion inhibiting peptides and derivatives thereof
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
MXPA04008275A (es) * 2002-02-28 2005-04-25 Microsens Biophage Ltd Enlace de formas patologicas de proteinas de prion.
DE60325519D1 (de) * 2002-03-01 2009-02-12 Hoffmann La Roche Doppel-transgenisches, nicht-humanes Säugertiermodell für die Alzheimer Krankheit
FR2837401B1 (fr) * 2002-03-25 2004-12-03 Commissariat Energie Atomique Procede de concentration de macromolecules ou agglomerats de molecules ou particules
NZ536054A (en) * 2002-04-09 2009-10-30 Scripps Research Inst Motif-grafted hybrid polypeptides and uses thereof
JP2004155688A (ja) 2002-04-30 2004-06-03 Biofrontier Kenkyusho:Kk シャペロン活性を有する合成ペプチド、脱炭酸活性の測定方法、伝達性海綿状脳症用薬剤及びその探索方法
US20060057636A1 (en) * 2002-08-21 2006-03-16 Peter Heegaard Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins
US20040072236A1 (en) * 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
NZ560410A (en) * 2002-12-03 2008-12-24 Univ North Carolina State Prion protein ligands and methods of use
US7510848B2 (en) * 2003-04-04 2009-03-31 North Carolina State University Prion protein binding materials and methods of use
US20070054322A1 (en) * 2003-07-31 2007-03-08 Hadasit Medical Research Services & Development Lt Methods and kits for the detection of prion diseases
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
WO2005016127A2 (en) 2003-08-13 2005-02-24 Chiron Corporation Prion-specific peptide reagents
JP3910569B2 (ja) * 2003-08-19 2007-04-25 独立行政法人科学技術振興機構 アミロイドβ蛋白質のアミロイド線維化を増幅するための試薬
EP1740951B1 (de) * 2004-04-29 2008-03-05 Marc Ramael Verfahren und kit zum nachweis von bestandteilen in einer probe
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
BRPI0607350A2 (pt) 2005-02-15 2009-09-01 Adlyfe Inc método para detecção da presença ou quantidade de uma proteìna erroneamente duplicada em uma amostra e kit
WO2006088281A1 (en) * 2005-02-19 2006-08-24 Peoplebio, Inc. Method for differentially detecting multimeric form from monomeric form of multimer-forming polypeptides
US8673579B2 (en) * 2006-07-28 2014-03-18 Adlyfe, Inc. Peptide probes for diagnostics and therapeutics
AU2009226161A1 (en) 2008-03-21 2009-09-24 Adlyfe, Inc. Use of pyrene to carry peptides across the blood brain barrier
US20090274621A1 (en) 2008-03-21 2009-11-05 Adlyfe, Inc Use of pyrene to carry non-peptide agents across the blood brain barrier
MX2011007916A (es) 2009-01-30 2011-11-18 Adlyfe Inc Péptidos conformacionalmente dinámicos.
US9556247B2 (en) 2010-05-25 2017-01-31 System Of Systems Analytics, Inc. Stabilized amyloid-beta oligomers and uses thereof
JP2014514576A (ja) 2011-04-27 2014-06-19 エイディーライフ インコーポレイティッド アミロイドタンパク質の眼における検出法

Also Published As

Publication number Publication date
EP2312312B1 (de) 2016-03-02
EP1700096A4 (de) 2007-11-21
JP4815355B2 (ja) 2011-11-16
AU2004297579A1 (en) 2005-06-23
EP1700096A2 (de) 2006-09-13
AU2010249147A1 (en) 2010-12-23
WO2005057166A3 (en) 2006-11-30
JP2007536502A (ja) 2007-12-13
EP2312312A2 (de) 2011-04-20
EP1700096B1 (de) 2011-09-21
US20050026165A1 (en) 2005-02-03
US9638702B2 (en) 2017-05-02
AU2004297579B2 (en) 2010-09-02
US20150233948A1 (en) 2015-08-20
WO2005057166A2 (en) 2005-06-23
CA2548812A1 (en) 2005-06-23
EP2312312A3 (de) 2011-08-03
US20080171341A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
ATE525649T1 (de) Nachweis von proteinen mit veränderter konformation
ATE424560T1 (de) Marker für neuromyelitis optica
ATE528649T1 (de) Verfahren zum nachweis falsch gefalteter proteine und prionen
ATE425266T1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
DE602006016589D1 (de) Neue markierungsstrategien für den empfindlichen nachweis von analyten
ATE490466T1 (de) Als interne funktionskontrolle in tests zum nachweis von seltenen zellen verwendete markierte zellen
FI20041323A (fi) Analysoija, järjestelmä ja menetelmä toivotun käyttäjäjoukon määrittämiseksi
ATE535805T1 (de) Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen
ATE549416T1 (de) Verfahren und zusammensetzungen zum nachweis von autoimmunkrankheiten
DE602006019404D1 (de) Docetaxel-immuntest
WO2007089372A3 (en) A position detecting system that self-monitors for connectivity faults
DE60328069D1 (de) Test-Photomaske, Streulichtbewertungsverfahren, und Streulichtkompensierungsverfahren
ATE476525T1 (de) Verfahren zum nachweis von mit endometrialer krankheit oder phase assoziierten markern
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
NL1032952A1 (nl) Polarisatie-evaluatiemasker, polarisatie-evaluatiewerkwijze en polarisatiebepalingsinrichting.
DE602004023180D1 (de) Informationsdetektionseinrichtung, -verfahren und -programm
ATE504833T1 (de) Verfahren zur bestimmung des phänotyps von zellen
ATE534905T1 (de) Cop1-moleküle und verwendungen davon
GB2437545B (en) Dextrin-containing reagents for detecting and quantifying proteins
BR0314155A (pt) Métodos para diagnosticar câncer cervical
ATE492815T1 (de) Diagnostik-biomolekül(e)
DE602006015702D1 (de) Unterscheidung zwischen baktiereller meningitis und viraler meningitis
WO2006012356A3 (en) Methods for determining risk of developing regular smoking behavior
WO2006096697A3 (en) Methods for determining the bivalency of protein and antibody therapeutics
DE602005020977D1 (de) Nachweis und quantifizierung von cyclodextrinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties